Fiscal Year Ending March 2026 3rd Quarter Financial Summary [Japanese GAAP] (Consolidated)

Performance Overview

In the cumulative consolidated period of the 3rd quarter of the fiscal year ending March 2026, net sales amounted to ¥214.986 billion (0.9% decrease YoY). Operating income was ¥4.623 billion (20.0% decrease YoY), ordinary income was ¥5.439 billion (16.0% decrease YoY), and net income attributable to owners of parent was ¥3.465 billion (13.1% decrease YoY), all declining from the previous year. While the domestic economy is on a moderate recovery trend, geopolitical risks and exchange rate fluctuations persist. The drugstore industry continues to face a severe environment due to intensified competition and consumer restraint caused by price increases. In response, we strengthened specialization in health foods and revised sales prices, implemented sales promotion measures such as the 65th anniversary campaign, and worked on inventory optimization.

Financial Condition and Outlook

Total assets were ¥205.095 billion (an increase of ¥5.493 billion from the previous fiscal year-end), total liabilities were ¥88.925 billion (an increase of ¥3.734 billion), and total net assets were ¥116.169 billion (an increase of ¥1.759 billion), resulting in an equity ratio of 56.6% (a decrease of 0.7 points). The number of stores expanded to 386 (including 159 stores with pharmacy). There is no change to the consolidated earnings forecast for the fiscal year ending March 2026, with expected net sales of ¥287.0 billion (0.3% decrease YoY), operating income of ¥6.0 billion (19.6% decrease YoY), and net income attributable to owners of parent of ¥3.7 billion (24.3% decrease YoY).